Join us at the Alumni Reception
Join us at our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar. All former and current residents, fellows, staff, spouses, companions and friends are welcome.
Where to Find Our Booth
Date |
Time |
Author |
Title |
Abstract |
Location |
| May 30 |
1:30 - 4:30p CDT |
Suneel Kamath, MD | Real-world conference of tumor mutational burden (TMB) between blood (circulating tumor DNA) and tissue, and its association with immunotherapy response. | Abstract: 2580 Poster: 370 |
Hall A |
| May 31 |
9a - 12p CDT | Wen Wee Ma, MBBS | Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non-small cell lung cancer: A phase 1/2 study. | Abstract: 8564 Poster: 354 |
Hall A |
| June 1 | 9a - 12p CDT |
Shahzad Raza, MD |
A machine learning (ML)-based six-gene signature for risk stratification and therapeutic target identification in multiple myeloma. | Abstract: 7558 Poster: 437 |
Hall A |
| June 1 |
9a - 12p CDT |
Faiz Anwer, MD |
Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies. | Abstract: 11055 Poster: 38 | Hall A |
| June 1 |
9a - 12p CDT |
Akriti Jain, MD | Timing of TP53 mutation acquisition as a determinant of outcomes in patients with myeloproliferative neoplasms and myeloproliferative neoplasms/myelodysplastic syndromes. | Abstract: 6587 Poster: 380 |
Hall A |
The cancer treatment landscape is changing, with new approvals coming fast and furious.
Catch up on what some of our physicians had to talk about at ASCO.
This year's ASCO conference highlighted the latest advances in treatments for solid tumors as well as blood cancers. Catch up on the latest in oncology research from Cleveland Clinic, including inhaled delivery of KB707, gene signatures in MM and predictive accuracy in solid tumors in our key abstracts below.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in.
Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, Abu Dhabi and coming soon in London, aiming to help cancer patients improve their quality of life and achieve long-term survival.
Cleveland Clinic provides world-class care to patients with cancer. Our nationally ranked cancer program is at the forefront of new and emerging clinical, translational and basic cancer research.
Dedicated to Advancing Cancer Care and Research
As a multidisciplinary, collaborative practice, we are committed to working with you to provide the best care for your patients, and to educate the next generation of medical professionals at all our facilities worldwide.
Abstracts to Watch for at ASCO 2026
The cancer treatment landscape is changing, with new approvals coming fast and furious. This year's ASCO conference is an opportune time to hear the latest advances in treatments for solid tumors as well as blood cancers.
Catch up on the latest in oncology research, including inhaled delivery of KB707, gene signatures in MM and predictive accuracy in solid tumors in our "must see" abstracts.
Save the Date
All former and current residents, fellows, staff, friends and spouses / companions of Cleveland Clinic are welcome to attend our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar.
| Date | Time | Title | Abstract/Poster# | Location |
|
May 31st
|
9 AM - 12 PM
|
Risk of Intracranial Hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases | 2034 | Hall A |
|
May 31st
|
9 AM - 12 PM
|
A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: ECOG-ACRIN EA2187 | 4115 | Hall A |
|
May 31st
|
1:30-4:30 PM
|
Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions. | 8643 | Hall A |
|
May 31st
|
1:15 PM
|
Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT) | 6000 | S100a |
|
June 3rd
|
12:09 PM
|
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 | 7508 | S100bc |
Roy Miller, MD
Roy Miller, MD
Our team is involved in many posters and presentations.
Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, London, and Abu Dhabi aiming to help cancer patients improve their quality of life and achieve long-term survival.
Watch our physician share key insights from the research he presented at ASCO.
Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study
Novel three-drug regimen used to manage life-threatening developments
Consult QD
A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.
Roy Miler, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.
S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.
Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.
Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.
Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.
Roy Miler, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.
S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.
Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.
Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.
Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.
Consult QD
A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.
S14 - A: Nullam in enim ullamcorper, efficitur dui a, fermentum erat. Cras in massa eget nisi imperdiet hendrerit vel interdum tellus. Ut pellentesque neque ipsum, quis fringilla nisl volutpat vel. Cras et luctus ipsum, quis blandit ligula. Morbi elementum tincidunt nibh eu lobortis. Ut consectetur ut libero sed sagittis.
S14 - A: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes
Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response
Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma
Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma
Research underscores the importance of access to timely diagnosis and treatment in this patient population.
TP53 Mutation Acquisition Timing Influence Prognosis in Myeloproliferative Neoplasms
Findings may help guide discussions around prognosis and allogeneic stem cell transplantation.
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Top Abstracts from ASCO 2026
Upcoming Events
10th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure
Cleveland, OH
Cleveland Clinic's AI Summit for Healthcare Professionals
Cleveland, OH
3rd Annual Cleveland Clinic Cancer Conference: Innovations in Multidisciplinary Care
Fort Lauderdale, FL
Subscribe to the Cancer Advances eNewsletter to get the latest Cleveland Clinic cancer-related research and insights.
Thank you for signing up.